Regular insulin was switched to rapid-acting insulin analogue in 12 type 1 diabetic patients undergoing continuous subcutaneous insulin infusion (CSII), and changes in glycemic control and QOL were studied for 6 months. Mean HbA
1c decreased from 8.4±2.1% at the switch to 8.1±1.7% after 1 month and 7.6±1.1% after 3 months. After 6 months, HbA
1c was 7.7±1.3% and was similar to the value at 3 months. Following the switch in treatment, hypoglycemia slightly increased, but nocturnal hypoglycemia decreased. No difference was seen in body weight before and after the switch.
A questionnaire conducted at 6 months showed that many subjects felt rapid-acting insulin analogue was more convenient to use. Based on these results, CSII with rapid-acting insulin analogue is considered useful in Japanese patients with type 1 diabetes.
View full abstract